Introduction
When someone first sees a skin disease, particularly when the skin starts to fall off for no reason, it can be really alarming. Probably, you are wondering what is happening, why it is happening, and what could be done about it. Fortunately, we are lucky that dermatological research has revealed many of these rare disorders, so that we are informed of what’s going on and what could be done for these patients.
If you or someone you know suffers from a rare skin peeling disease, you are not alone. Although little is known about it, rare skin peeling diseases have been recognised and grouped, and a dermatologist can help with a proper diagnosis, treatment, and long-term care.1,2 In this essay, I’ll be talking about what it is, how it happens, how it is diagnosed, what treatment options are available, and what it means to those who live with it.
Overview
Rare skin peeling disease is also known as Peeling Skin Syndrome (PSS). It is a group of inherited skin disorders in which the outermost layer of the skin separates too easily from the layers beneath. In other words, the skin peels off or sheds from the body, either constantly or in occasional bursts.
Unlike burn, eczema, or blistering disorder, PSS is pain-free. Most of those affected first experience symptoms soon after birth or within the first few years of life, and the peeling may persist for the rest of their lives. Although not life-threatening, PSS can cause discomfort, dry skin, cosmetic problems, and an increased risk of skin infections.
PKS is caused by genetic mutations in the genes responsible for producing structural proteins in the skin, such as corneodesmosin (CDSN) or transglutaminase 5 (TGM5) [3.4]. Symptoms typically appear at birth or within the first few years of life.
Symptoms include:
- Continuous or episodic skin peeling
- Redness and irritation, particularly after being rubbed or exposed to heat5
- Dryness, scaling, and flaking
- In some cases, blistering
Diagnosis is based on the clinical presentation, family history, skin biopsy, and sometimes genetic testing.3,6
There is no permanent cure for this condition, but the focus of treatment is on supportive care — moisturisers, emollients, keratolytic cream, and infection prevention.2,7
PSS isn’t a single disease, but rather a spectrum of related disorders. Each is associated with slightly different genetic abnormalities and clinical features. In order to have a better idea of what it is like to live with PSS, let’s take a closer look at the categorisation, diagnostic tests, treatment options, and long-term outlook.
Types of peeling skin syndrome
Since PSS refers to a group of disorders with similar clinical features, researchers grouped them together and classified them into types based on the gene affected and the clinical presentation. There are two major categories:
1. Non-inflammatory PSS:
- In this type, the skin peels continuously, but without redness or inflammation6
- Sometimes in sheets or large flakes, which peel off painlessly
- Most commonly caused by mutations in the CHST8 gene (which codes for carbohydrate sulfotransferase8
2. Inflammatory PSS:
- As above, with redness, irritation, and sometimes mild blistering
- Symptoms can be worse in hot, humid weather
- Often caused by mutations in CDSN or TGM5
Other subtypes are also known, and scientists are discovering new gene mutations associated with different types of the disorder.5,8
Diagnosis
Because rare diseases can mimic other, more common disorders, a proper diagnosis is crucial. Doctors will likely first rule out other conditions such as eczema, psoriasis, or ichthyosis (another disorder characterised by scaling of the skin).
- Medical history and family history: Because the disorder is genetic, it often affects multiple family members
- Clinical examination: A dermatologist examines the pattern, degree, and causes of skin peeling
- Skin biopsy: A dermatologist takes a small skin sample and examines it under the microscope. Under the microscope, one can see that the skin separates into the upper layers
- Genetic testing: New genetic testing can identify mutations in genes known to cause PSS, confirming the diagnosis
Diagnosis not only helps identify the source of peeling but also helps families understand how the disorder will be inherited.
Treatment and management
There is no cure for Peeling Skin Syndrome, but the disorder can be greatly relieved and the quality of life improved with proper management.
Supportive care
- Moisturisers and emollients: These help keep skin moist and reduce the appearance of peeling. Popular options include petroleum jelly, glycerin-based creams, and ceramide-containing creams and lotions
- Keratolytic agents: Creams containing either urea, lactic acid, or salicylic acid can help remove stubborn scales.
- Antihistamines: If present, these may help relieve itching
- Antibiotics or antifungals: If an infected secondary skin infection is present, oral or topical medications may be prescribed
- Avoiding triggers: Dermatologists often recommend avoiding excessive heat and humidity or rubbing and friction, which can exacerbate peeling
Research into gene therapy and targeted treatments for PSS is ongoing, but these are not yet available.9
Daily life with PSS
Living with a chronic rare disorder can present numerous challenges. Children may be bullied by classmates, who find their skin appearance unusual. Adults may need to plan activities to avoid flare-ups and spend time each day caring for their skin. Joining a support group or reaching out to a rare disease network can provide patients and families with useful information and resources.
Despite these challenges, many people with PSS live long, healthy lives. With careful daily care, serious complications are rare.
Research and future directions
While PSS may be rare, dermatologists, geneticists, and molecular biologists have taken notice because it offers a window into the skin barrier.
The stratum corneum — the outermost protective layer of the skin that keeps water out and pathogens in, and maintains homeostasis — is crucial to the physiology of the skin. In PSS, genetic mutations lead to failure of this barrier. Because of this, PSS offers a distinct “natural model” for studying skin physiology.
In the last 10 years, the use of whole-exome sequencing and next-generation sequencing technology has revolutionised our knowledge of PSS. We now know that several genes — CDSN, TGM5, CHST8, and FLG26,3,4,8— are mutated and cause the disorder. All of these genes code for proteins involved in cell adhesion or cornification (which gives the skin its structure). Researchers have now begun to identify potential targets for gene therapy or RNA-based treatments for PSS — if not this decade, then perhaps the next.
One possibility is using CRISPR-Cas9 gene editing to correct the defective gene in skin cells grown in a lab. These corrected cells could then be transplanted back onto patients as skin grafts, helping restore normal function to the affected areas.10,11 Of course, this is a long way off from the clinic. However, proof-of-concept studies in similar genetic skin disorders (such as epidermolysis bullosa) have shown that it is a possibility.
Other potential treatments include biologic therapies or topical drugs that could improve skin cohesion or compensate for the missing proteins. For example, a compound that improves barrier function, reduces inflammation, or stabilises desmosomes (the “glue” that holds skin cells together) could offer some relief. Another novel approach is to use stem cell therapy in which healthy skin stem cells are introduced to repopulate the damaged skin.
Finally, personalised medicine is also on the rise. Because PSS is not one homogeneous disorder, but rather a group of syndromes with different gene defects, tailoring treatment to the patient’s specific mutation will likely become the standard of care for PSS in the future.
There is no cure for PSS, but there is hope. Interdisciplinary collaboration between international rare disease networks, patient advocacy groups, and biomedical researchers is rapidly driving discoveries in this area. Hopefully, patients will not only be able to manage their symptoms but also one day receive disease-modifying therapies that target the underlying cause of their condition.
Summary
PKS is a rare inherited disorder characterised by painless, continuous shedding of the skin. It results from genetic mutations in barrier proteins and is typically diagnosed in early childhood.
There is no cure, but diagnosis can be confirmed via clinical examination and genetic testing. Treatment revolves around alleviating symptoms and providing supportive care. Moisturisers, keratolytic creams, and infection prevention are the primary forms of management. Life expectancy is normal, but may be affected by discomfort and cosmetic issues.
With numerous potential treatments being explored, the future of this skin disease appears promising, particularly with advancements in genetics and dermatology.
FAQ's
Is Peeling Skin Syndrome contagious?
No. It is an inherited genetic mutation, and can't be contracted from another person.
Can the disease be cured?
As of now, there is no cure. Treatment for PSS revolves around managing symptoms.
How is it different from eczema or psoriasis?
Eczema and psoriasis are an inflamed and typically itchy condition, whereas PSS results in painless peeling due to defects in the structure of skin proteins.
What treatments are available?
Moisturisers and emollients, keratolytic cream, antihistamine pills or cream, and antibiotic cream or pills if infection occurs.
Does PSS affect life expectancy?
Not normally. People with PSS can expect to live a normal lifespan. However, regular care is necessary to ensure healthy skin.
Can children get the disease?
Yes. Since it is a genetic disease, it can be passed to children if both parents carry the faulty gene. Genetic counselling can offer advice to families.
What kind of lifestyle adjustments can help?
Avoiding heat and friction, wearing soft clothing, and following a moisturising routine every day can help make symptoms less troublesome.
Are there support groups?
Yes. There are organisations dedicated to rare diseases and dermatology patient groups that can offer community and resources to those with PSS.
References
- Bowden PE. Peeling skin syndrome: genetic defects in late terminal differentiation of the epidermis. J Invest Dermatol. 2011 Mar;131(3):561–4. doi:10.1038/jid.2010.434. PMID:21307953.
- Peeling skin syndrome. National Organization for Rare Disorders (NORD). 2020. Available from: https://rarediseases.org/rare-diseases/peeling-skin-syndrome/
- Oji V, Eckl KM, Aufenvenne K, Nätebus M, Tarinski T, Ackermann K, et al. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. Am J Hum Genet. 2010 Aug 13;87(2):274–81. doi:10.1016/j.ajhg.2010.07.005. PMID:20691404. PMCID:2917721.
- Cassidy AJ, van Steensel MA, Steijlen PM, van Geel M, van der Velden J, Morley SM, et al. A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome. Am J Hum Genet. 2005 Dec;77(6):909–17. doi:10.1086/497707. PMID:16380904. PMCID:1285176.
- Mohamad J, Sarig O, Godsel LM, Peled A, Malchin N, Bochner R, et al. Filaggrin 2 deficiency results in abnormal cell-cell adhesion in the cornified cell layers and causes peeling skin syndrome Type A. J Invest Dermatol. 2018 Aug;138(8):1736–43. doi:10.1016/j.jid.2018.04.032. PMID:29758285. PMCID:6056331.
- Cabral RM, Kurban M, Wajid M, Shimomura Y, Petukhova L, Christiano AM. Whole-exome sequencing in a single proband reveals a mutation in the CHST8 gene in autosomal recessive peeling skin syndrome. Genomics. 2012 Apr;99(4):202–8. doi:10.1016/j.ygeno.2012.01.005. PMID:22289416. PMCID:4362535.
- Singhal A, Kurra S, Sankineni N, et al. A case of peeling skin syndrome. [Case report]. 2017. PMCID:5447344.
- Valentin F, et al. Development of a pathogenesis-based therapy for peeling skin syndrome. Br J Dermatol. 2021 Jun;184(6):1123–1130. doi:10.1111/bjd.19439. PMID:33450000.
- Baker C, et al. Gene editing in dermatology: Harnessing CRISPR for the skin. Br J Dermatol. 2020; (review). PMID:32645678. PMCID:7265575.
- Marinkovich MP. Gene Therapy for Epidermolysis Bullosa. J Invest Dermatol. 2019; (review). PMID:31068252.11. De Rosa L, et al. Stairways to advanced therapies for epidermolysis bullosa. Clin Transl Med. 2023; (review). PMCID:10071437.

